Hubbry Logo
RubellaRubellaMain
Open search
Rubella
Community hub
Rubella
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Rubella
Rubella
Rubella
View on Wikipedia
from Wikipedia

Rubella
Other namesGerman measles, three-day measles
A rash due to rubella on a child's back. The area affected is similar to that of measles but the rash is less intensely red.
SpecialtyInfectious disease
SymptomsRash, swollen lymph nodes, fever, sore throat, feeling tired[1][2]
ComplicationsTesticular swelling, inflammation of nerves, congenital rubella syndrome, miscarriage[1][3]
Usual onset2 weeks after exposure[1]
Duration3 days[1]
CausesRubella virus (spread through the air)[3][4]
Diagnostic methodFinding the virus in the blood, throat, or urine, antibody tests[1]
PreventionRubella vaccine[3]
TreatmentSupportive care[2]
Frequency17,865 cases (2022) [5]

Rubella, also known as German measles or three-day measles,[6] is an infection caused by the rubella virus.[3] This disease is often mild, with half of people not realizing that they are infected.[1][7] A rash may start around two weeks after exposure and last for three days.[1] It usually starts on the face and spreads to the rest of the body.[1] The rash is sometimes itchy and is not as bright as that of measles.[1] Swollen lymph nodes are common and may last a few weeks.[1] A fever, sore throat, and fatigue may also occur.[1][2] Joint pain is common in adults.[1] Complications may include bleeding problems, testicular swelling, encephalitis, and inflammation of nerves.[1] Infection during early pregnancy may result in a miscarriage or a child born with congenital rubella syndrome (CRS).[3] Symptoms of CRS manifest as problems with the eyes such as cataracts, deafness, as well as affecting the heart and brain.[3] Problems are rare after the 20th week of pregnancy.[3]

Rubella is usually spread from one person to the next through the air via coughs of people who are infected.[3][4] People are infectious during the week before and after the appearance of the rash.[1] Babies with CRS may spread the virus for more than a year.[1] Only humans are infected.[3] Insects do not spread the disease.[1] Once recovered, people are immune to future infections.[3] Testing is available that can verify immunity.[3] Diagnosis is confirmed by finding the virus in the blood, throat, or urine.[1] Testing the blood for antibodies may also be useful.[1]

Rubella is preventable with the rubella vaccine, with a single dose being more than 95% effective.[3] Often it is given in combination with the measles vaccine and mumps vaccine, known as the MMR vaccine.[1] When some, but less than 80%, of a population is vaccinated, more women may reach childbearing age without developing immunity by infection or vaccination, thus possibly raising CRS rates.[3] Once infected there is no specific treatment.[2]

Rubella is a common infection in many areas of the world.[2] Each year about 100,000 cases of congenital rubella syndrome occur.[3] Rates of disease have decreased in many areas as a result of vaccination.[2][7] There are ongoing efforts to eliminate the disease globally.[3] In April 2015, the World Health Organization declared the Americas free of rubella transmission.[8][9] The name "rubella" is from Latin and means little red.[1] It was first described as a separate disease by German physicians in 1814, resulting in the name "German measles".[1]

Signs and symptoms

[edit]
Young boy displaying the characteristic maculopapular rash of rubella[10]
Generalized rash on the abdomen due to rubella

Rubella has symptoms similar to those of flu. However, the primary symptom of rubella virus infection is the appearance of a rash (exanthem) on the face which spreads to the trunk and limbs and usually fades after three days, which is why it is often referred to as three-day measles. The facial rash usually clears as it spreads to other parts of the body. Other symptoms include low-grade fever, swollen glands (sub-occipital and posterior cervical lymphadenopathy), joint pains, headache, and conjunctivitis.[11]

The swollen glands or lymph nodes can persist for up to a week and the fever rarely rises above 38 °C (100.4 °F). The rash of rubella is typically pink or light red. The rash causes itching and often lasts for about three days. The rash disappears after a few days with no staining or peeling of the skin. When the rash clears up, the skin might shed in very small flakes where the rash covered it. Forchheimer spots occur in 20% of cases and are characterized by small, red papules on the area of the soft palate.[12]

Rubella can affect anyone of any age. Adult females are particularly prone to arthritis and joint pains.[13]

In children, rubella normally causes symptoms that last two days and include:

  • Rash begins on the face which spreads to the rest of the body.
  • Low fever of less than 38.3 °C (100.9 °F).
  • Posterior cervical lymphadenopathy.[14]

In older children and adults, additional symptoms may be present, including[citation needed]

  • Swollen glands
  • Coryza (cold-like symptoms)
  • Aching joints (especially in young females)

Severe complications of rubella include:

Coryza in rubella may convert to pneumonia, either direct viral pneumonia or secondary bacterial pneumonia, and bronchitis (either viral bronchitis or secondary bacterial bronchitis).[16]

Congenital rubella syndrome

[edit]
Main article: Congenital rubella syndrome
Child with cataracts in both eyes due to congenital rubella syndrome

Rubella can cause congenital rubella syndrome in the newborn, this being the most severe sequela of rubella. The syndrome (CRS) follows intrauterine infection by the rubella virus and comprises cardiac, cerebral, ophthalmic, and auditory defects.[17] It may also cause prematurity, low birth weight, neonatal thrombocytopenia, anemia, and hepatitis. Neurodevelopmental disorders, including autism, are common.[18]

The risk of major defects in organogenesis is highest for infection in the first trimester. CRS is the main reason a vaccine for rubella was developed.[19] 80–90% of mothers who contract rubella within the critical first trimester have either a miscarriage or a stillborn baby.[11]

If the fetus survives the infection, it can be born with severe heart disorders (patent ductus arteriosus being the most common), blindness, deafness, or other life-threatening organ disorders. The skin manifestations are called "blueberry muffin lesions".[19] For these reasons, rubella is included in the TORCH complex of perinatal infections.[20][21]

About 100,000 cases of this condition occur each year.[3]

Cause

[edit]
Main article: Rubella virus
Transmission electron micrograph of rubella viruses

The disease is caused by the rubella virus, in the genus Rubivirus from the family Matonaviridae,[22] that is enveloped and has a single-stranded RNA genome.[23] The virus is transmitted by the respiratory route and replicates in the nasopharynx and lymph nodes. The virus is found in the blood 5 to 7 days after infection and spreads throughout the body. The virus has teratogenic properties and is capable of crossing the placenta and infecting the fetus where it stops cells from developing or destroys them.[11] During this incubation period, the patient is contagious typically for about one week before he/she develops a rash and for about one week thereafter.[1]

Increased susceptibility to infection might be inherited as there is some indication that HLA-A1 or factors surrounding A1 on extended haplotypes are involved in virus infection or non-resolution of the disease.[24][25]

Diagnosis

[edit]

Rubella virus specific IgM antibodies are present in people recently infected by rubella virus, but these antibodies can persist for over a year, and a positive test result needs to be interpreted with caution.[26] The presence of these antibodies along with, or a short time after, the characteristic rash confirms the diagnosis.[27]

Prevention

[edit]
Further information: MMR vaccine

Rubella infections are prevented by active immunization programs using live attenuated virus vaccines. Two live attenuated virus vaccines, RA 27/3 and Cendehill strains, were effective in the prevention of adult disease. However, their use in prepubertal females did not produce a significant fall in the overall incidence rate of CRS in the UK. Reductions were only achieved by immunisation of all children.[28]

The vaccine is now usually given as part of the MMR vaccine. The WHO recommends the first dose be given at 12 to 18 months of age with a second dose at 36 months. Pregnant women are usually tested for immunity to rubella early on. Women found to be susceptible are not vaccinated until after the baby is born because the vaccine contains live virus.[29]

The immunisation program has been quite successful. Cuba declared the disease eliminated in the 1990s, and in 2004 the Centers for Disease Control and Prevention announced that both the congenital and acquired forms of rubella had been eliminated from the United States.[30][31] The World Health Organization declared Australia rubella free in October 2018.[32]

Screening for rubella susceptibility by history of vaccination or by serology is recommended in the United States for all women of childbearing age at their first preconception counseling visit to reduce incidence of congenital rubella syndrome (CRS).[33] It is recommended that all susceptible non-pregnant women of childbearing age should be offered rubella vaccination.[33] Due to concerns about possible teratogenicity, use of MMR vaccine is not recommended during pregnancy.[33] Instead, susceptible pregnant women should be vaccinated as soon as possible in the postpartum period.[33]

In susceptible people passive immunization, in the form of polyclonal immunoglobulins, appears effective up to the fifth day post-exposure.[34]

Treatment

[edit]

There is no specific treatment for rubella; however, management is a matter of responding to symptoms to diminish discomfort. Treatment of newborn babies is focused on management of the complications. Congenital heart defects and cataracts can be corrected by direct surgery.[13][35]

Management for ocular congenital rubella syndrome (CRS) is similar to that for age-related macular degeneration, including counseling, regular monitoring, and the provision of low vision devices, if required.[36]

Prognosis

[edit]

Rubella infection of children and adults is usually mild, self-limiting, and often asymptomatic. The prognosis in children born with CRS is poor.[37]

Epidemiology

[edit]

Rubella occurs worldwide. The virus tends to peak during the spring in countries with temperate climates. Before the vaccine against rubella was introduced in 1969, widespread outbreaks usually occurred every 6–9 years in the United States and 3–5 years in Europe, mostly affecting children in the 5–9 year old age group.[38] Since the introduction of vaccine, occurrences have become rare in those countries with high uptake rates.[citation needed]

Vaccination has interrupted the transmission of rubella in the Americas: no endemic case has been observed since February 2009.[39] Vaccination is still strongly recommended as the virus could be reintroduced from other continents should vaccination rates in the Americas drop.[40] During the epidemic in the US between 1962 and 1965, rubella virus infections during pregnancy were estimated to have caused 30,000 stillbirths and 20,000 children to be born impaired or disabled as a result of CRS.[41][42] Universal immunisation producing a high level of herd immunity is important in the control of epidemics of rubella.[43]

In the UK, there remains a large population of men susceptible to rubella who have not been vaccinated. Outbreaks of rubella occurred amongst many young men in the UK in 1993 and in 1996 the infection was transmitted to pregnant women, many of whom were immigrants and were susceptible. Outbreaks still arise, usually in developing countries where the vaccine is not as accessible.[44] The complications encountered in pregnancy from rubella infection (miscarriage, fetal death, congenital rubella syndrome) are more common in Africa and Southeast Asia at a rate of 121 per 100,000 live births compared to 2 per 100,000 live births in the Americas and Europe.[45]

In Japan, 15,000 cases of rubella and 43 cases of congenital rubella syndrome were reported to the National Epidemiological Surveillance of Infectious Diseases between October 15, 2012, and March 2, 2014, during the 2012–13 rubella outbreak in Japan. They mainly occurred in men aged 31–51 and young adults aged 24–34.[46]

History

[edit]
See also: Eradication of infectious diseases § Rubella

Rubella was first described in the mid-eighteenth century. German physician and chemist, Friedrich Hoffmann, made the first clinical description of rubella in 1740,[47] which was confirmed by de Bergen in 1752 and Orlow in 1758.[48]

In 1814, George de Maton first suggested that it be considered a disease distinct from both measles and scarlet fever. All these physicians were German, and the disease was known as Rötheln (contemporary German Röteln). (Rötlich means "reddish" or "pink" in German.) The fact that three Germans described it led to the common name of "German measles."[49] Henry Veale, an English Royal Artillery surgeon, described an outbreak in India. He coined the name "rubella" (from the Latin word, meaning "little red") in 1866.[47][50][51][52]

It was formally recognised as an individual entity in 1881, at the International Congress of Medicine in London.[53] In 1914, Alfred Fabian Hess theorised that rubella was caused by a virus, based on work with monkeys.[54] In 1938, Hiro and Tosaka confirmed this by passing the disease to children using filtered nasal washings from acute cases.[51]

In 1940, there was a widespread epidemic of rubella in Australia. Subsequently, ophthalmologist Norman McAllister Gregg found 78 cases of congenital cataracts in infants and 68 of them were born to mothers who had caught rubella in early pregnancy.[50][51] Gregg published an account, Congenital Cataract Following German Measles in the Mother, in 1941. He described a variety of problems now known as congenital rubella syndrome (CRS) and noticed that the earlier the mother was infected, the worse the damage was. Since no vaccine was yet available, some popular magazines promoted the idea of "German measles parties" for infected children to spread the disease to other children (especially girls) to immunize them for life and protect them from later catching the disease when pregnant.[55] The virus was isolated in tissue culture in 1962 by two separate groups led by physicians Paul Douglas Parkman and Thomas Huckle Weller.[50][52]

There was a pandemic of rubella between 1962 and 1965, starting in Europe and spreading to the United States.[52] In the years 1964–65, the United States had an estimated 12.5 million rubella cases (1964–1965 rubella epidemic). This led to 11,000 miscarriages or therapeutic abortions and 20,000 cases of congenital rubella syndrome. Of these, 2,100 died as neonates, 12,000 were deaf, 3,580 were blind, and 1,800 were intellectually disabled. In New York alone, CRS affected 1% of all births.[56][57]

In 1967, the molecular structure of rubella was observed under electron microscopy using antigen-antibody complexes by Jennifer M. Best, June Almeida, J E Banatvala and A P Waterson.[58][59]

In 1969, a live attenuated virus vaccine was licensed.[51] In the early 1970s, a triple vaccine containing attenuated measles, mumps and rubella (MMR) viruses was introduced.[52] By 2006, confirmed cases in the Americas had dropped below 3000 a year. However, a 2007 outbreak in Argentina, Brazil, and Chile pushed the cases to 13,000 that year.[8]

Eradication efforts

[edit]

On January 22, 2014, the World Health Organization (WHO) and the Pan American Health Organization declared and certified Colombia free of rubella and became the first Latin American country to eliminate the disease within its borders.[60][61] On April 29, 2015, the Americas became the first WHO region to officially eradicate the disease. The last non-imported cases occurred in 2009 in Argentina and Brazil. The Pan American Health Organization director remarked, "The fight against rubella has taken more than 15 years, but it has paid off with what I believe will be one of the most important pan-American public health achievements of the 21st Century."[62] The declaration was made after 165 million health records and genetically confirming that all recent cases were caused by known imported strains of the virus. Rubella is still common in some regions of the world and Susan E. Reef, team lead for rubella at the CDC's global immunization division, who joined in the announcement, said there was no chance it would be eradicated worldwide before 2020.[8] Rubella is the third disease to be eliminated from the Western Hemisphere with vaccination after smallpox and polio.[8][9]

Etymology

[edit]

From "rubrum" the Latin for "red", rubella means "reddish and small". "German" measles derives from "germanus" which means "similar" in this context.[63]

The name rubella is sometimes confused with rubeola, an alternative name for measles in English-speaking countries; the diseases are unrelated.[64][65] In some other European languages, like Spanish, rubella and rubeola are synonyms, and rubeola is not an alternative name for measles. Thus, in Spanish, rubeola refers to rubella and sarampión refers to measles.[66][67]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Rubella

View on Grokipedia
from Grokipedia
Rubella, also known as German measles, is a contagious viral infection caused by the rubella virus, a single-stranded RNA virus in the genus Rubivirus of the family Matonaviridae, that primarily affects children and young adults but can occur at any age. The disease is transmitted through respiratory droplets from coughing or sneezing, with humans serving as the only natural hosts, and is most infectious from one week before to about one week after the onset of the characteristic rash. While typically mild, with symptoms including a maculopapular rash starting on the face and spreading to the body, low-grade fever, and posterior auricular lymphadenopathy, approximately 25% to 50% of infections are asymptomatic. The incubation period for rubella averages 17 days (ranging from 12 to 23 days), and the illness usually resolves within three days, earning it the alternative name "three-day measles." Complications are uncommon in children but more frequent in adults, particularly women, who may experience or in up to 70% of cases; rare severe effects include thrombocytopenic purpura or . The most significant risk arises during , especially in the first trimester, where maternal carries a 90% transmission risk to the , potentially leading to (CRS) in the newborn. CRS is a leading vaccine-preventable cause of birth defects worldwide, affecting an estimated 32,000 infants in 2019 (with modeling suggesting around 36,000 in 2023), with lifelong conditions such as , congenital cataracts, congenital heart defects, and developmental delays. Diagnosis relies on laboratory confirmation rather than clinical presentation alone, due to similarities with other rash illnesses like or parvovirus; methods include (PCR) testing of nasopharyngeal swabs, throat swabs, or urine, and serological detection of rubella-specific IgM antibodies. There is no specific antiviral treatment for rubella; is supportive, focusing on symptom relief, isolation to prevent spread (for seven days after rash onset), and for pregnant individuals. Prevention is highly effective through with the measles-mumps-rubella (MMR) or its MMRV variant, which provides lifelong immunity in over 95% of recipients after one dose and nearly 100% after two doses. The is recommended in two doses for children—at 12 to 15 months and 4 to 6 years—and for susceptible adults, particularly those born after 1957 or at risk of exposure. Globally, rubella remains a concern despite significant progress; the (WHO) reported 17,865 cases across 78 countries in 2022, a 97% reduction from 670,894 cases in 2000, attributed to expanded programs. As of 2025, 19 countries have not introduced rubella-containing vaccines, accounting for approximately 78% of the global CRS burden. In the United States, rubella was declared eliminated in 2004, with fewer than 10 cases annually, mostly import-related, due to high coverage exceeding 90%. The WHO's Global and Rubella Strategic Plan aims for elimination in all regions by 2030, with 175 of 194 countries having introduced rubella-containing vaccines by January 2024, achieving 69% first-dose coverage. Continued surveillance and efforts are essential to prevent outbreaks and reduce the burden of CRS in low-coverage areas.

Clinical Presentation

Signs and Symptoms in Acquired Rubella

Acquired rubella, also known as postnatal rubella , typically presents as a mild illness, particularly in children where it is often subclinical or features only low-grade fever and a mild or no rash. In adults, the illness may be somewhat more pronounced, with similar rash and fever but additional complications such as arthralgia or arthritis. The ranges from 12 to 23 days and an average of 17 days. During this period, the virus replicates in the nasopharynx and regional lymph nodes before disseminating systemically. The prodromal phase, which lasts 1 to 5 days and is more pronounced in older children and adults, often includes low-grade fever, , , and . Additional upper respiratory symptoms such as coryza (runny nose) and may occur, along with and general discomfort. A hallmark feature is the characteristic , which emerges 14 to 17 days after exposure and begins on the face before spreading to the trunk and limbs within 24 hours. The rash is typically milder and fainter than that of , lasting about 3 days, which has earned rubella the nickname "three-day measles." It appears in 50% to 80% of infected individuals. Lymphadenopathy precedes the rash by approximately 5 to 7 days and primarily involves the postauricular, occipital, and posterior , persisting for up to several weeks. This enlargement may be tender and is a key early sign, often noticeable before other symptoms. Other manifestations include or , which affect up to 70% of adolescent and adult females and are less common in children or males; these joint symptoms, which can be painful and last for weeks to months, typically involve the fingers, wrists, and knees. Rare features encompass mild , Forschheimer spots (petechiae on the ), and, in males, testalgia or . Rare complications also include encephalitis, occurring in approximately 1 in 6,000 cases. Notably, up to 50% of rubella infections are asymptomatic or subclinical, allowing for unrecognized transmission despite the absence of clinical signs. In contrast to the generally benign course of acquired rubella, infection during pregnancy can lead to severe congenital rubella syndrome in the fetus.

Congenital Rubella Syndrome

Congenital rubella syndrome (CRS) arises from rubella virus infection in utero, resulting in multisystem congenital anomalies that can profoundly affect the infant's health and development. The hallmark features form a classic triad: sensorineural deafness, which is the most common manifestation occurring in up to 80% of cases; congenital cataracts, affecting the lens and leading to visual impairment; and congenital heart defects, particularly patent ductus arteriosus and pulmonary stenosis. These defects stem from the virus's teratogenic effects during critical periods of organogenesis, often leading to lifelong disabilities if untreated. Beyond the triad, CRS encompasses a broader array of manifestations, including with associated , causing or tendencies, with elevated liver enzymes, and radiolucent lesions visible on radiographs as a characteristic "celery stalking" pattern in the metaphyses of long bones. Endocrine disorders, such as insulin-dependent diabetes mellitus and thyroid dysfunction, may emerge later in childhood or adolescence, contributing to ongoing health challenges. These varied symptoms highlight the virus's widespread interference with fetal growth and organ maturation. The severity and likelihood of CRS depend heavily on the gestational timing of maternal , with the highest risk in the first trimester—up to 90% chance of major defects if infection occurs through week 10, and up to 85% within the first 12 weeks. Risk diminishes progressively thereafter, dropping to about 50% between weeks 13 and 16, 25% in the latter second trimester, and rarely causing defects after 20 weeks, though late infections may still result in fetal death or . Survivors of CRS often face long-term sequelae, including progressive sensorineural hearing loss that may worsen over time, persistent visual impairment from cataracts or glaucoma, and neurodevelopmental delays manifesting as cognitive impairments or behavioral issues. These enduring effects underscore the importance of early intervention, though no curative treatment exists for the syndrome itself.

Etiology and Pathogenesis

Virology

(RUBV) is the sole member of the Rubivirus in the family Matonaviridae. It is an enveloped, spherical, pleomorphic virus with a of approximately 60–70 nm, featuring a derived from the host studded with heterodimers of the glycoproteins E1 and E2 arranged in helical rows. The internal nucleocapsid core, measuring 30–35 nm, consists of the protein surrounding the genome. The is a single-stranded, positive-sense molecule of approximately 9.7 kb, capped at the 5′ end and polyadenylated at the 3′ end. It comprises two non-overlapping open reading frames (ORFs): the 5′ proximal ORF (~6.3 kb) encodes a polyprotein precursor (p200) that is cleaved into non-structural proteins, including the replicase components p150 ( and activities) and p90 ( and other functions); the 3′ proximal ORF (~3.2 kb) encodes a polyprotein (p110) processed into the structural proteins, including the protein C and the envelope glycoproteins E1 (fusion and hemagglutination functions) and E2 (cell attachment). A subgenomic is produced from an internal promoter to facilitate structural protein translation. The replication cycle initiates with viral attachment to host cell receptors, potentially including (MOG), mediated by the E2 glycoprotein, followed by clathrin-dependent . Endosomal acidification to pH 6.0–6.2 triggers calcium-dependent fusion via the E1 glycoprotein, releasing the nucleocapsid into the for uncoating and genome release. The positive-sense genomic is directly translated by host ribosomes to produce the non-structural polyprotein, which forms replication complexes associated with intracellular membranes, particularly the . The (from p150) synthesizes a negative-sense RNA intermediate, which serves as a template for new positive-sense genomic and subgenomic RNAs in cytoplasmic vesicles. Structural proteins are translated from the subgenomic ; the protein C assembles with genomic to form nucleocapsids, which bud into the and Golgi membranes incorporating E1 and E2, maturing into enveloped virions released by . Replication primarily occurs in the , with the entire cycle taking 12–24 hours in susceptible cells. RUBV exhibits a single antigenic , with neutralizing epitopes predominantly located on the E1 (e.g., residues 223–239), while E2 contributes to broader immune recognition but is less immunogenic. Despite antigenic stability, arises mainly in the E1 coding region, enabling phylogenetic classification. The designates two major clades (differing by 8–10% nucleotide sequence in the 3′ genome third) encompassing 13 , with 1 (subgenotypes 1E, 1G, 1J) predominant worldwide and 2B circulating regionally. involves sequencing 739 of the E1 (positions 8731–9469) compared to reference strains. As an enveloped virus, RUBV demonstrates limited environmental stability, being highly sensitive to (inactivated after 30 minutes at 56°C), light, common disinfectants (e.g., , ), and . It is also unstable at extremes (<6.8 or >8.1), though it can persist in aerosolized droplets or dried secretions for weeks to months under cool, humid conditions before losing infectivity.

Transmission

Rubella virus is primarily transmitted from person to person through respiratory droplets generated by coughing, sneezing, or talking from infected individuals, with nasopharyngeal secretions serving as the main source of infectious particles. The virus is highly contagious, exhibiting a secondary of 50-90% among susceptible household contacts. Humans represent the only known , as there is no evidence of sustained animal or environmental reservoirs facilitating transmission. The infectious period typically spans 7 days before the onset of the characteristic to 7 days after, with peak contagiousness occurring around the time the rash erupts; however, infants with can shed viable virus for up to 1 year postnatally, prolonging their potential to transmit. is highest in throat swabs during the prodromal phase, underscoring the role of close contact in spread. Following , the virus initially replicates in the epithelial cells of the nasopharynx and associated regional lymph nodes, leading to localized infection within 2-3 days. By days 5-7 post-infection, develops as the virus disseminates systemically via infected mononuclear cells, culminating in endothelial cell involvement that manifests as the macular and potential multi-organ effects. In pregnant individuals, maternal enables transplacental transmission, where the virus crosses the placental barrier during the first trimester, primarily infecting cells and fetal endothelial cells, which can result in widespread fetal organ damage. Transmission to the is most efficient early in , with rates approaching 90% if exposure occurs before 10 weeks. Key risk factors for rubella transmission include in settings such as schools or households, which facilitates droplet spread, and low population-level coverage that sustains susceptible pools. While the can survive briefly on environmental surfaces—losing infectivity within hours under ambient conditions— transmission is negligible compared to airborne droplet dissemination.

Diagnosis

Clinical Assessment

Clinical assessment of suspected rubella begins with a detailed history to identify risk factors and establish the timeline of illness. Key elements include inquiring about recent exposure to confirmed or suspected cases, as the spreads via respiratory droplets and is contagious from seven days before to seven days after onset. Vaccination status should be reviewed, with two doses of the providing near-complete protection. In women of childbearing age, status and are critical, given the high risk of fetal transmission (up to 90% in the first trimester). Travel to or residence in endemic areas, where vaccination coverage is low, raises suspicion. The typically lasts 14 to 21 days, followed by a of low-grade fever, , mild coryza, and lasting one to five days, which is more pronounced in adults than children. Physical examination focuses on characteristic findings to support clinical suspicion. Inspection reveals a in 50% to 80% of cases, starting on the face and before spreading to the trunk and extremities within 24 hours; it is pink, blanching, and fades after two to three days without . identifies tender , particularly postauricular, suboccipital, and posterior cervical nodes, often preceding the rash by up to a week. Joint assessment may uncover or , affecting up to 70% of adult cases, especially women, and resolving within days to weeks. Ocular examination can detect mild or, less commonly, —small petechiae on the —in about 20% of patients. Differential diagnosis is essential due to overlapping features with other exanthems. Measles presents with higher fever, cough, coryza, , and spots, alongside a more confluent . Scarlet fever involves , strawberry tongue, and a sandpaper-like with , often linked to group A Streptococcus. Parvovirus B19 causes a "slapped " appearance on the face, with a lacy on the body, but lacks prominent . Enteroviral exanthems, such as those from , feature vesicular lesions or a more widespread without the specific pattern of rubella. Special considerations heighten urgency in certain scenarios. In pregnant individuals, immediate evaluation is vital due to the potential for , with risks of or fetal defects if infection occurs early in ; counseling on options like termination may be warranted before 18 weeks. During outbreaks, particularly in unvaccinated communities, the index of suspicion increases, prompting broader surveillance. Severity indicators include rare complications such as , occurring in approximately 1 in 6,000 cases and potentially fatal, or in about 1 in 3,000 to 6,000 cases, manifesting as petechiae or . These warrant prompt recognition, though most infections remain mild and self-limited. Laboratory confirmation via or PCR is recommended to verify in atypical or high-risk presentations.

Laboratory Methods

Laboratory diagnosis of rubella primarily relies on serological assays to detect virus-specific antibodies and molecular techniques to identify viral RNA, with virus isolation serving as a confirmatory but less commonly used method due to its time-intensive nature. Serological testing involves enzyme immunoassays (EIAs) for rubella-specific immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies. Rubella IgM antibodies, indicative of acute infection, typically appear 4-5 days after rash onset and are detectable for up to 30 days in postnatal cases, though they may persist for 3-6 months in congenital rubella syndrome (CRS); optimal sensitivity (>90%) is achieved when serum is collected 5 or more days post-rash. A fourfold or greater rise in rubella IgG antibodies between acute- and convalescent-phase serum specimens, collected 2-3 weeks apart, confirms recent infection, while stable high levels of IgG indicate prior immunity. IgG avidity testing, performed via EIA with urea or diethylamine denaturation, helps differentiate recent (low avidity) from past (high avidity) infections, particularly useful in early pregnancy to assess timing of maternal exposure. Molecular detection of RNA is highly sensitive during early and employs real-time (RT-PCR) targeting conserved regions such as the E1 . Specimens include nasopharyngeal or throat swabs, urine, or serum collected within 1-7 days of symptom onset for acute cases, with dual collection (e.g., swab and urine) increasing yield; in CRS, urine or throat swabs from infants are preferred before 3 months of age, as may continue up to 1 year. Endpoint RT-PCR is additionally used for to investigate outbreaks and track virus transmission, amplifying specific genomic regions for . Virus isolation remains the gold standard for confirmation but is rarely performed outside reference laboratories due to its slow turnaround (up to 2-3 weeks) and requirements. Clinical specimens are inoculated onto susceptible cell lines such as Vero or rabbit cornea cells, incubated at 35°C, and monitored for cytopathic effects like cell degeneration, followed by staining for confirmation using rubella-specific monoclonal antibodies. Emerging rapid diagnostic tests (RDTs) for rubella-specific IgM, developed as of 2025 under the Global Measles and Rubella Laboratory Network, offer point-of-care potential in low-resource settings. These lateral flow assays, using serum or , provide results in 15-20 minutes with 90-91% sensitivity and 94-96% specificity; however, they remain in prototype stage without standalone commercial products for rubella, often combined with diagnostics. For prenatal diagnosis of fetal rubella infection, maternal rubella IgG testing assesses immunity, while suspected acute maternal infection prompts RT-PCR on amniotic fluid obtained via amniocentesis (after 15 weeks gestation) or chorionic villus sampling (CVS) to detect viral RNA directly in fetal tissues. Detection of rubella-specific IgM in fetal blood or viral RNA in amniotic fluid confirms intrauterine infection, often combined with fetal ultrasound to identify anomalies associated with CRS. Interpretation of laboratory results can be challenging due to potential false-positive IgM results from cross-reactivity with other pathogens (e.g., or ) or , as well as transient IgM detection following recent measles-mumps-rubella (MMR) , which may mimic acute infection. In such cases, IgG avidity testing or molecular confirmation is essential to avoid misdiagnosis, particularly in pregnant individuals where unnecessary termination decisions could arise.

Prevention

Vaccination

The is a live attenuated preparation, primarily using the RA 27/3 strain, which is administered either as a standalone or in combination with and vaccines as the measles-mumps-rubella (MMR) vaccine. This strain-based vaccine was licensed in , replacing earlier versions, though initial rubella vaccines were introduced in 1969. The RA 27/3 strain induces a robust that closely mimics natural , producing higher antibody titers compared to prior strains. The demonstrates high , with approximately 97% protection against clinical rubella disease following two doses. It confers lifelong immunity in the majority of recipients, significantly reducing transmission and preventing outbreaks. In populations with high coverage, the incidence of has declined by more than 99% compared to the pre-vaccine era. Routine vaccination schedules recommend two doses of : the first at 12–15 months of age and the second at 4–6 years of age. Catch-up vaccination is advised for unvaccinated or under-vaccinated adults, with particular emphasis on women of childbearing age to prevent . Vaccination policies and subsidy programs for adults can vary by country and region. For example, in Suginami Ward (杉並区), Tokyo, Japan, general subsidies for adult measles-rubella (MR) vaccines are not implemented. However, rubella-specific measures include subsidies for antibody testing and vaccination costs for women planning pregnancy and their spouses/partners, as well as for men born between April 2, 1962, and April 1, 1979, under national rubella additional measures. No subsidies exist for measles-only vaccines or general adult MR vaccines. Contraindications include , due to the live component, and severe , as the could cause disseminated infection in such individuals. should be avoided for 4 weeks following vaccination as a precaution. Achieving requires 80–85% population coverage to interrupt rubella transmission effectively. The (WHO) targets at least 95% coverage with the first dose of rubella-containing through routine to support global elimination efforts. Common side effects are mild and self-limited, including fever in 5–15% of recipients and a transient in approximately 5%, typically occurring 7–12 days post-vaccination. Serious adverse events, such as , are rare, occurring at rates of about 1 per million doses.

Infection Control Measures

Infection control for rubella emphasizes prompt isolation, targeted screening, and coordinated outbreak responses to limit transmission, particularly in vulnerable settings such as healthcare facilities and communities with pregnant individuals. Individuals diagnosed with rubella should be excluded from school, work, or other congregate settings for at least 7 days after rash onset to prevent droplet spread via respiratory secretions. In healthcare environments, droplet precautions are recommended, including use of surgical masks for patients and gowns/gloves for personnel during close contact. Screening for rubella immunity plays a key role in preventing congenital infections, with serologic testing recommended for women preconception or during routine if prior immunity is uncertain. Postpartum assessment of immunity status allows for targeted interventions in non-immune women to protect future pregnancies. During outbreaks, rapid identifies exposed individuals from 7 days before to 7 days after the index case's rash onset, prioritizing household and high-risk contacts such as pregnant women. Enhanced surveillance involves active case searches, broadened diagnostic criteria (e.g., including fever and without rash), and collaboration with local health departments to monitor for 6 weeks retrospectively and prospectively. Ring of susceptible contacts, alongside isolation of cases, forms part of the response, though efficacy complements broader efforts. Additionally, aspirin should be avoided in children with rubella due to the rare but serious risk of Reye's syndrome. Travel to rubella-endemic regions warrants pre-travel immunity verification, with requiring proof of for certain destinations to curb importation risks. options are limited; routine after exposure does not reliably prevent , and immune (IG) is not recommended for most contacts as it does not halt but may attenuate symptoms. Immune is not recommended for against rubella, including in pregnant women, as it does not prevent or . Susceptible exposed pregnant women should undergo serologic monitoring and activity restrictions for up to 6 weeks post-exposure.

Management

Treatment Approaches

Rubella infection is managed primarily through supportive care, as there is no specific antiviral available to treat the or hasten recovery. Symptoms such as fever, , and are typically mild and self-limiting in children and adults, resolving within a few days to weeks without intervention. Supportive measures focus on symptom relief and include bed rest, adequate hydration, and antipyretics like acetaminophen to control fever and discomfort. Aspirin should be avoided in children and adolescents due to the risk of Reye's syndrome associated with viral infections. For pruritus associated with the , topical lotion or oral antihistamines may provide relief, particularly in adults. Management of complications is targeted and supportive. Arthritis, which occurs in up to 70% of adult women but is rare in children, is treated with rest and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen to alleviate and swelling; corticosteroids are not indicated. Thrombocytopenic , another potential complication, is usually self-limited but requires intravenous immunoglobulin (IVIG) for severe cases with significant risk; platelet transfusions may be considered if hemorrhage occurs, while corticosteroids show no proven benefit. Rare immune-mediated issues, such as , warrant supportive care including fluid and electrolyte , with no specific antiviral or immunomodulatory therapy available. No licensed antivirals exist for rubella, though has been used experimentally in cases of persistent congenital rubella infection, particularly in immunocompromised infants, but it is not standard due to potential toxicity and uncertain efficacy. In pregnant individuals, rubella infection necessitates close fetal monitoring via serial ultrasounds to detect signs of (CRS), such as cardiac defects or , especially if infection occurs in the first trimester. Counseling regarding the high risk of , , or CRS (affecting up to 90% of fetuses in early ) should include discussion of management options, including therapeutic if infection is confirmed before 12 weeks' . For confirmed CRS in newborns, management is supportive, involving multidisciplinary care for defects like or cataracts, with surgical interventions as needed for structural anomalies. Hospitalization is reserved for cases with requiring intravenous fluids, neurological complications like needing supportive monitoring, or severe congenital defects in infants that mandate immediate surgical evaluation. With appropriate supportive care, most uncomplicated cases recover fully without long-term sequelae.

Prognosis

For acquired rubella in children and adults, the prognosis is generally excellent, with most cases being mild and self-limited, leading to full recovery within approximately one week as the rash resolves in about three days and other symptoms subside shortly thereafter. Mortality is rare, estimated at less than 0.1% of cases, and primarily results from complications such as (occurring in about 1 in 6,000 cases) or , which are more common and severe in immunocompromised individuals. or , which affects up to 70% of adult women, typically resolves within days to a month, though it may persist longer in some cases. In contrast, congenital rubella syndrome (CRS) carries a high risk of morbidity and mortality, with up to 33% of affected infants dying before their first birthday, often due to severe complications like , , or . Among survivors, the risk of sensorineural is substantial, affecting 50% to 90% depending on the study cohort and timing, while visual impairments such as cataracts or occur in 10% to 50% of cases, and congenital heart defects (e.g., ) necessitating surgical intervention affect 10% to 50%. Late-onset complications include type 1 diabetes mellitus, with risks of 10% to 40% by age 35 in survivors, alongside increased chances of dysfunction and progressive neurological issues. Prognosis for CRS is heavily influenced by the at maternal , with risks exceeding 85% for defects if occurs in the first trimester but dropping to 25% or less in the second trimester, and by maternal immunity status, as prior or prevents fetal transmission. Overall, widespread rubella since its introduction in has dramatically improved outcomes by reducing global reported cases by 97% from 2000 to 2022, averting millions of CRS instances; as of 2024, global CRS cases are estimated at around 32,000 annually. For CRS survivors, long-term often requires multidisciplinary follow-up involving for hearing aids or implants, for defect monitoring, and for developmental support to manage lifelong disabilities.

Epidemiology

Global Distribution and Burden

Rubella has been eliminated as an endemic disease in the Region of the Americas since 2015, following verification by the Pan American Health Organization, and significant progress toward elimination has been achieved in parts of the European Region and the Western Pacific Region through high vaccination coverage. However, the virus remains endemic in the WHO African Region, South-East Asia Region, and Eastern Mediterranean Region, where vaccination introduction and coverage lag behind, leading to ongoing transmission. By the end of 2024, 178 of 194 countries had introduced rubella-containing vaccines, but global coverage stands at 73%, with the lowest rates in these persistent regions, facilitating sustained circulation among susceptible populations. The global burden of rubella is primarily driven by (CRS), which results from maternal infection during pregnancy and causes severe birth defects including , cataracts, and heart anomalies. In the pre-vaccine era, an estimated 100,000 infants were born annually with CRS worldwide. efforts have substantially reduced this burden; mathematical modeling estimates that by , the global number of CRS cases had declined by approximately two-thirds to 32,000 (95% : 13,000–60,000) annually, averting over 229,000 cases between 2010 and 2019. Recent modeling for 2024 estimates approximately 36,000 global CRS cases, with 78% occurring in the 19 countries without introduction. The burden remains disproportionately high in low-income countries with vaccination coverage below 80%, where the majority of CRS cases occur, underscoring the disease's impact on child health and healthcare systems in resource-limited settings. Unvaccinated children serve as key reservoirs for rubella transmission, while pregnant women in endemic areas face the highest risk of adverse outcomes, including , , or CRS in their . There is no inherent disparity in CRS defects, as the affects fetuses regardless of , but affected females often experience amplified societal burdens, such as barriers to and in certain cultures. Socioeconomic factors exacerbate vulnerability; and armed conflicts disrupt routine programs and surveillance, resulting in lower uptake and recurrent outbreaks in affected communities. Prior to the introduction of widespread rubella vaccination, the disease exhibited a characteristic cyclical pattern, with major epidemics occurring every 6 to 9 years, often peaking in spring and affecting large populations of children and young adults. These cycles were driven by the accumulation of susceptible individuals between outbreaks, leading to widespread transmission in unvaccinated communities. Global incidence of rubella has declined dramatically following vaccine introduction, with reported cases dropping 97% from 670,894 in 2000 across 102 countries to 17,865 in 2022 across 78 countries, according to (WHO) surveillance data. This reduction is attributed to increasing vaccination coverage, which reached 73% globally for the first dose of rubella-containing by the end of 2024, though resurgence risks persist in under-vaccinated pockets where coverage falls below the 95% threshold needed for . For instance, localized outbreaks continue to emerge in areas with low rates, highlighting vulnerabilities to importation and secondary spread. Recent outbreaks illustrate these patterns, including a notable surge in Poland during 2018–2019, where 437 cases were reported in 2018 and 292 laboratory-confirmed cases in 2019, primarily among unvaccinated adolescents and young adults. In , ongoing transmission continued into 2025. reported 11,705 confirmed rubella cases in 2024. As of 2025, 1,627 laboratory-confirmed cases have been reported in 2025, mostly among children under 15 years in unvaccinated communities. Surveillance efforts are integrated through the WHO and Centers for Disease Control and Prevention (CDC) Global Measles and Rubella Laboratory Network (GMRLN), which supports case detection, confirmation, and virus tracking across 743 laboratories worldwide using measles-rubella surveillance systems. Genotyping of viruses, such as the prevalent genotype 2B circulating in Asia, enables monitoring of importations and endemic chains, with over 5,700 sequences analyzed from 2012–2022 showing 42% as genotype 2B. Modeling projections indicate that introducing rubella-containing vaccines in the remaining countries could avert nearly 1 million CRS cases from 2025 to 2055, though threats from and population migration could sustain risks in low-coverage areas. The Americas maintain verified elimination of endemic rubella since 2015, with no indigenous transmission reported. In highly vaccinated regions, (CRS) incidence has fallen below 10% of pre-vaccine levels, with estimates showing over 90% reduction in areas achieving sustained high coverage, compared to global pre-vaccine rates of up to 100,000 CRS cases annually.

History

Discovery and Early Understanding

Rubella was first described in the by German physicians as "rötheln," referring to the characteristic red that distinguished it from more severe illnesses like or . By the early , it was increasingly recognized as a distinct entity; in 1814, George Maton provided one of the earliest clinical descriptions in English literature, noting its mild nature with , , and minimal fever, separate from . German medical literature further solidified this distinction between 1814 and the 1850s, leading to its common English name "German measles" due to these origins. The disease's naming evolved in 1866 when British physician Henry Veale proposed "rubella," derived from the Latin word for "red," to describe an outbreak in and emphasize the rash's appearance over its geographic association. Early epidemiological observations portrayed rubella as a generally mild, self-limited childhood infection, with epidemics recurring every 6 to 9 years in temperate climates, building up as cohorts of susceptible children accumulated. In the pre-vaccine era, annual reported incidence in places like the averaged around 47,000 cases, though underreporting of mild infections likely underestimated the true burden, resulting in attack rates of approximately 1-2% annually among susceptible populations during inter-epidemic periods. A pivotal advancement came in 1941 when Australian ophthalmologist Norman Gregg observed a link between maternal rubella infections during early pregnancy—amid 1939-1940 outbreaks—and congenital defects in newborns, including cataracts, heart anomalies, and deafness, establishing rubella's teratogenic potential. This insight shifted perceptions from a benign illness to one with severe implications. Confirmation of its viral cause followed in 1962, when the was independently isolated in by Paul Parkman, Harry Meyer, and colleagues at Walter Reed Army Institute, and by Thomas Weller and Franklin Neva at Harvard, enabling definitive diagnosis and paving the way for further research.

Vaccine Development and Eradication Efforts

The development of the rubella vaccine began in the mid-1960s following the isolation of the virus, with initial efforts focusing on live attenuated strains. The HPV-77 strain, developed by Paul Parkman and colleagues at the Walter Reed Army Institute of Research, was licensed in the United States in 1969 after adaptation through serial passage in rabbit kidney and duck embryo cells. However, this strain was associated with a higher incidence of transient arthritis, particularly in adult women, leading to its voluntary withdrawal from the market in 1979. It was replaced by the RA 27/3 strain, isolated by Stanley Plotkin in 1969 from human diploid fibroblasts derived from aborted fetal tissue and further attenuated through 25–30 passages. The RA 27/3 vaccine demonstrated superior safety, immunogenicity, and efficacy, inducing seroconversion in over 95% of recipients while producing fewer adverse reactions like arthralgia compared to HPV-77. Licensed in the United States in 1979 and widely adopted globally, it remains the standard strain today. In 1971, Merck & Co., under Maurice Hilleman, combined the RA 27/3 rubella component with measles and mumps vaccines to form the MMR vaccine, facilitating efficient delivery and improving uptake through a single formulation. Eradication efforts for rubella have been guided by (WHO) strategic frameworks, emphasizing high vaccination coverage to interrupt transmission and prevent (CRS). The Global Vaccine Action Plan (2011–2020) set a target of 95% coverage with two doses of rubella-containing vaccine in all countries by 2015, with regional elimination goals for at least five WHO regions by 2020. The Region of the achieved verified rubella elimination in 2015, becoming the first to do so through sustained high coverage and surveillance. The European Region aimed for elimination by 2015 but faced delays due to suboptimal coverage in several countries; as of August 2025, 50 of the 53 member states have verified elimination, though regional verification is pending. As of 2022, 98 countries (51% of WHO members) had verified elimination; by September 2025, additional verifications in and 21 Pacific island countries and areas have been achieved. In September 2025, WHO verified rubella elimination in and across 21 Pacific island countries and areas. Global elimination by 2030, as outlined in the Immunization Agenda 2030, appears unlikely without addressing coverage gaps. Key initiatives include the & Rubella Partnership, launched in 2001 by WHO, , the , CDC, and others, which coordinates global vaccination campaigns and surveillance. The GAVI Alliance has supported introduction in low-income countries since 2011, contributing to efforts that have enabled 88 countries to integrate rubella-containing into routine programs; the Measles & Rubella Partnership has supported delivery of over 3.86 billion doses of measles and rubella since 2001. Challenges persist in conflict-affected zones, such as parts of and the , where access is limited, and has risen, exacerbated by COVID-19-related disruptions in 2020–2022 that stalled campaigns and reduced coverage. of circulating rubella strains plays a critical role in verifying transmission interruption by distinguishing endemic from imported cases during elimination assessments. Progress is evident in global first-dose coverage of measles-rubella vaccine reaching 83% in 2023, up from lower levels in the early , though second-dose coverage lags at 74%. Rubella has led to a 97% decline in reported cases since 2000, significantly reducing the burden of CRS, through widespread introduction in 175 countries by 2023. Future strategies emphasize integration with other routine immunizations, such as pentavalent vaccines, and enhanced subnational targeting to close immunity gaps and achieve sustainable elimination.

References

  1. https://www.cdc.gov/rubella/hcp/clinical-overview/index.html
  2. https://www.who.int/news-room/fact-sheets/detail/rubella
  3. https://www.ncbi.nlm.nih.gov/books/NBK559040/
  4. https://www.ijidonline.com/article/S1201-9712(23)00715-4/fulltext
  5. https://www.cdc.gov/mmwr/volumes/74/wr/mm7418a3.htm
  6. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-20-rubella.html
  7. https://www.cdc.gov/rubella/signs-symptoms/index.html
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC1001829/
  9. https://archive.cdc.gov/www_cdc_gov/ncbddd/birthdefects/surveillancemanual/chapters/chapter-5/chapter5-1.html
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC6801530/
  11. https://www.ncbi.nlm.nih.gov/books/NBK507879/
  12. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6212a3.htm
  13. https://ictv.global/report/chapter/matonaviridae/matonaviridae
  14. https://www.ncbi.nlm.nih.gov/books/NBK8200/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC8139664/
  16. https://doi.org/10.1128/JVI.05398-11
  17. https://doi.org/10.1099/0022-1317-77-2-303
  18. https://archive.cdc.gov/www_cdc_gov/rubella/lab/genetic-analysis.html
  19. https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/lab_networks/measles_rubella/rubella-nomemclature-report.pdf?sfvrsn=751e8270_3
  20. https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/lab_networks/measles_rubella/manual/chapter-1.pdf?sfvrsn=f7f1fc1d_2
  21. https://academic.oup.com/ije/article/1/3/261/752146
  22. https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/rubella-virus.html
  23. https://www.merckmanuals.com/professional/pediatrics/common-viral-infections-in-infants-and-children/rubella
  24. https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-14-rubella.html
  25. https://www.cdc.gov/rubella/php/laboratories/index.html
  26. https://www.cdc.gov/rubella/php/laboratories/serology-testing.html
  27. https://www.cdc.gov/rubella/php/laboratories/rna-detection.html
  28. https://www.who.int/docs/default-source/immunization/vpd_surveillance/lab_networks/measles_rubella/manual/chapter-6.pdf
  29. https://cdn.who.int/media/docs/default-source/immunization/vpd_surveillance/lab_networks/measles_rubella/manual/chapter-5.pdf?sfvrsn=3553af4c_2
  30. https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(25)00252-5
  31. https://www.who.int/docs/default-source/immunization/vpd_surveillance/lab_networks/measles_rubella/manual/chapter-4.pdf?sfvrsn=ec496bf2_2
  32. https://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf
  33. https://www.cdc.gov/mmwr/preview/mmwrhtml/00053391.htm
  34. https://www.cdc.gov/rubella/vaccines/index.html
  35. https://www.city.suginami.tokyo.jp/
  36. https://www.cdc.gov/vaccines/hcp/imz-best-practices/contraindications-precautions.html
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC10458369/
  38. https://www.who.int/publications/i/item/WHO-WER9527
  39. https://www.immunize.org/wp-content/uploads/catg.d/p4218.pdf
  40. https://www.cdc.gov/vaccine-safety/vaccines/mmr.html
  41. https://www.cdc.gov/infection-control/hcp/isolation-precautions/appendix-a-type-duration.html
  42. https://www.cdc.gov/mmwr/preview/mmwrhtml/00001893.htm
  43. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5012a1.htm
  44. https://wwwnc.cdc.gov/travel/page/travel-vaccines
  45. https://www.cdc.gov/rubella/about/index.html
  46. https://emedicine.medscape.com/article/968523-treatment
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC11844209/
  48. https://gpnotebook.com/pages/infectious-disease/rubella-in-pregnant-mother
  49. https://www.ecdc.europa.eu/en/rubella/factsheet
  50. https://www.cdc.gov/global-rubella-vaccination/data-research/facts-stats/index.html
  51. https://emedicine.medscape.com/article/968523-clinical
  52. https://www.ecdc.europa.eu/en/congenital-rubella-syndrome
  53. https://www.mdpi.com/1660-4601/16/19/3543
  54. https://www.paho.org/en/topics/rubella
  55. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC10689248/
  57. https://www.cidrap.umn.edu/rubella/routine-rubella-vaccination-19-countries-could-avert-1-million-cases-2055-data-suggest
  58. https://www.cdc.gov/mmwr/volumes/73/wr/mm7308a2.htm
  59. https://www.cdc.gov/rubella/pregnancy/index.html
  60. https://www.sciencedirect.com/science/article/pii/S1201971217301923
  61. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5411a5.htm
  62. https://pubmed.ncbi.nlm.nih.gov/33570312/
  63. https://www.cdc.gov/mmwr/volumes/70/wr/mm7023a1.htm
  64. https://www.nicd.ac.za/wp-content/uploads/2025/11/Weekly-measles_outbreak_sitrep_week-44_final.pdf
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC12595551/
  66. https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/surveillance/surveillance-for-vpds/laboratory-networks/measles-and-rubella-laboratory-network
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC6731519/
  68. https://www.infectiousdiseaseadvisor.com/news/rubella-containing-vaccination-reduces-congenital-rubella-syndrome-incidence/
  69. https://historyofvaccines.org/history/stanley-plotkin-md/timeline/
  70. https://pubmed.ncbi.nlm.nih.gov/3890105/
  71. https://www.sciencedirect.com/science/article/abs/pii/S014067362102691X
  72. https://www.cdc.gov/surv-manual/php/table-of-contents/chapter-15-congenital-rubella-syndrome.html
  73. https://www.mayoclinic.org/diseases-conditions/history-disease-outbreaks-vaccine-timeline/rubella
  74. https://www.cambridge.org/core/services/aop-cambridge-core/content/view/F740ABC2F5BE5418DCFEE7F1667E91A2/S0950268800048640a.pdf/rubella_vaccines_past_present_and_future.pdf
  75. https://www.nvic.org/disease-vaccine/rubella/vaccine-history
  76. https://www.who.int/publications/i/item/measles-and-rubella-strategic-framework-2021-2030
  77. https://www.who.int/westernpacific/news/item/26-09-2025-rubella-elimination-verified-in-japan--and-measles-and-rubella-elimination-verified-in-pacific-island-countries-and-areas
  78. https://measlesrubellapartnership.org/the-partnership/
  79. https://www.gavi.org/types-support/vaccine-support/measles-and-measles-rubella
  80. https://measlesrubellapartnership.org/learn/about-us/
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.